[Geneco]

To evaluate the role of SARS-CoV-2/CCCoV-specific Abs in severe COVID-19 pathogenesis and immunity, we analyzed plasma levels of SARS-CoV-2/CCCoV IgG, IgA and IgM Abs of the SARS-CoV-2 infected patients. Assessment of Ab levels between these patient populations revealed some, but not definitive differences that stratified outcome. The SARS-CoV-2-S specific IgG/IgM Abs levels/titers of the younger Vax patients (19-49 years) were consistently higher than those of the NVax patients (Figure 3A). Further, non-survivors had lower SARS-CoV-2 N/CCCoV N Ab levels/titer compared to those patients who survived, and this trend was more pronounced in the Vax group (Figures 3B and Supplementary Figure 3). Additionally, the SARS-CoV-2-N specific IgG/IgA/IgM Abs titers of the NVax patients were significantly higher than those of the Vax patients (Figure 3C). Interestingly, NVax patients with comorbidities had higher SARS-CoV-2 specific Ab levels compared to their Vax counterparts (Supplementary Figure 3), suggesting that the presence of comorbidities was not the sole contributing factor to the decreased Ab response.

Thus, contrary to our expectations, we observed decreased Ab levels in the Vax compared to the NVax group